



REPORTED SALES vs. PRIOR PERIOD
\$MM

	2007				
	Q1	Q2	Q3	Q4	Ful Year
PHARMACEUTICAL SEGMENT ^{(2) (3)}					
<u>ACIPHEX/PARIET</u>					
US	159	161	159	166	645
Intl	177	175	179	181	712
WW	336	336	338	347	1,357
<u>CONCERTA</u>					
US	200	199	177	222	798
Intl	52	57	54	67	230
WW	252	256	231	289	1,028
<u>DURAGESIC/FENTANYL TRANSDERMAL</u>					
US	116	96	107	72	391
Intl	187	192	202	192	773
WW	303	288	309	264	1,164
<u>LEVAQUIN/FLOXIN</u>					
US	459	344	352	409	1,564
Intl	20	20	19	23	82
WW	479	364	371	432	1,646
<u>PROCRIPT/EPREX</u>					
US	530	449	380	331	1,690
Intl	287	309	302	297	1,195
WW	817	758	682	628	2,885
<u>RAZADYNE/REMINYL</u>					
US	51	51	43	49	194
Intl	77	81	87	92	337
WW	128	132	130	141	531
<u>REMICADE</u>					
US	600	625	648	661	2,534
US Exports ⁽⁴⁾	131	244	171	246	792
Intl	0	0	0	1	1
WW	731	869	819	908	3,327
<u>RISPERDAL</u>					
US	559	540	530	570	2,199
Intl	308	308	301	304	1,221
WW	867	848	831	874	3,420
<u>RISPERDAL CONSTA</u>					
US	101	102	111	108	422
Intl	160	176	183	187	706
WW	261	278	294	295	1,128
<u>TOPAMAX</u>					
US	501	472	498	535	2,006
Intl	109	106	115	117	447
WW	610	578	613	652	2,453
<u>VELCADE</u>					
US	2	1	2	3	8
Intl	111	125	128	162	526
WW	113	126	130	165	534
<u>OTHER</u>					
US	625	576	587	572	2,361
Intl	699	740	764	829	3,032
WW	1,324	1,316	1,351	1,402	5,393
<u>TOTAL PHARMACEUTICAL</u>					
US	4,034	3,860	3,765	3,944	15,603
Intl	2,187	2,289	2,334	2,453	9,263
WW	6,221	6,149	6,099	6,397	24,866

⁽¹⁾ Operational growth excludes the effect of currency

⁽²⁾ Select areas (unaudited)

⁽³⁾ Prior year amounts have been reclassified to conform with current presentation

⁽⁴⁾ For external purposes, reported as U.S. sales



REPORTED SALES vs. PRIOR PERIOD
\$MM

	2007				
	<u>Q1</u>	<u>Q2</u>	<u>Q3</u>	<u>Q4</u>	<u>Ful Year</u>
<u>MEDICAL DEVICES AND DIAGNOSTICS</u> ^{(2) (3)}					
<u>CORDIS</u>					
US	424	397	373	394	1,588
Intl	504	455	404	474	1,837
WW	928	852	777	868	3,425
<u>DEPUY</u>					
US	678	663	636	661	2,638
Intl	479	472	450	548	1,949
WW	1,157	1,135	1,086	1,209	4,587
<u>DIABETES CARE</u>					
US	292	310	321	337	1,260
Intl	257	286	264	306	1,113
WW	549	596	585	643	2,373
<u>ETHICON</u> ⁽⁴⁾					
US	345	351	350	353	1,399
Intl	529	553	531	591	2,204
WW	874	904	881	944	3,603
<u>ETHICON ENDO-SURGERY</u>					
US	417	454	440	481	1,792
Intl	474	503	482	583	2,042
WW	891	957	922	1,064	3,834
<u>ORTHO-CLINICAL DIAGNOSTICS</u> ⁽⁴⁾					
US	233	231	235	245	944
Intl	175	190	185	211	761
WW	408	421	420	456	1,705
<u>VISION CARE</u>					
US	195	213	214	190	812
Intl	318	340	363	376	1,397
WW	513	553	577	566	2,209
<u>TOTAL MEDICAL DEVICES AND DIAGNOSTICS</u>					
US	2,584	2,619	2,569	2,661	10,433
Intl	2,736	2,799	2,679	3,089	11,303
WW	5,320	5,418	5,248	5,750	21,736

⁽¹⁾ Operational growth excludes the effect of currency

⁽²⁾ Select areas (unaudited)

⁽³⁾ Prior year amounts have been reclassified to conform with current presentation

⁽⁴⁾ Restated to include portion of sales previously reported in the "Other" category



REPORTED SALES vs. PRIOR PERIOD
\$MM

CONSUMER SEGMENT ⁽²⁾

SKIN CARE

	Q1	Q2	Q3	Q4	Ful Year
US	357	338	311	323	1,329
Intl	407	419	426	470	1,722
WW	764	757	737	793	3,051

BABY CARE

US	109	106	113	116	444
Intl	338	381	398	421	1,538
WW	447	487	511	537	1,982

ORAL CARE

US	203	186	211	189	789
Intl	156	167	185	190	699
WW	359	353	396	379	1,488

OTC/NUTRITIONALS

US	655	584	653	728	2,620
Intl	602	622	611	687	2,522
WW	1,257	1,206	1,264	1,415	5,142

WOMEN'S HEALTH

US	163	164	149	148	623
Intl	258	299	312	313	1,183
WW	421	463	461	461	1,806

WOUND CARE / OTHER

US	142	184	154	122	603
Intl	106	114	100	103	421
WW	248	298	254	225	1,024

TOTAL CONSUMER

US	1,629	1,562	1,591	1,626	6,408
Intl	1,867	2,002	2,032	2,184	8,085
WW	3,496	3,564	3,623	3,810	14,493

⁽¹⁾ Operational growth excludes the effect of currency

⁽²⁾ Select areas (unaudited)